Skip to main content
. 2018 Sep 14;10(9):329. doi: 10.3390/cancers10090329

Table 2.

Pharmaceutical agents directly modulating YAP-TEAD interaction.

Active Compound Common Name Mechanism of Action Indication References
graphic file with name cancers-10-00329-i012.jpg Digitoxin Na+/K+ ATPase inhibitor Congestive cardiac insufficiency
Heart failure		 [59,60,61]
graphic file with name cancers-10-00329-i013.jpg Verteporfin Photodynamic agent Subfoveal Choroidal Neovascularization [28,62,63,64,65,66,67]
graphic file with name cancers-10-00329-i014.jpg Flufenamic Acid COX-inhibitor NSAID [68]